F

Fortrea Holdings Inc
NASDAQ:FTRE

Watchlist Manager
Fortrea Holdings Inc
NASDAQ:FTRE
Watchlist
Price: 19.36 USD 0.99% Market Closed
Market Cap: 1.7B USD
Have any thoughts about
Fortrea Holdings Inc?
Write Note

Gross Margin
Fortrea Holdings Inc

18.5%
Current
18%
Average
44.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
18.5%
=
Gross Profit
513m
/
Revenue
2.8B

Gross Margin Across Competitors

Country US
Market Cap 1.7B USD
Gross Margin
18%
Country US
Market Cap 1.2T USD
Gross Margin
55%
Country US
Market Cap 201.2B USD
Gross Margin
41%
Country US
Market Cap 166.9B USD
Gross Margin
60%
Country KR
Market Cap 66.5T KRW
Gross Margin
49%
Country CH
Market Cap 38.7B CHF
Gross Margin
29%
Country US
Market Cap 38.8B USD
Gross Margin
55%
Country US
Market Cap 36.3B USD
Gross Margin
35%
Country US
Market Cap 26.8B USD
Gross Margin
59%
Country US
Market Cap 24.2B USD
Gross Margin
35%
Country US
Market Cap 22.2B USD
Gross Margin
60%
No Stocks Found

Fortrea Holdings Inc
Glance View

Market Cap
1.7B USD
Industry
Life Sciences Tools & Services

Fortrea Holdings Inc. operates in the dynamic sphere of Contract Research Organizations (CRO), carving out a niche in the healthcare and biopharmaceutical industries by providing essential services to companies looking to bring new medicinal products and treatments to market. At its core, Fortrea specializes in conducting clinical trials, integrating advanced data analytics, and ensuring regulatory compliance, vital for pharmaceutical firms that often lack the infrastructure to manage these complex processes internally. By offering an array of services—from initial research design through to the final stages of clinical trials—Fortrea positions itself as a critical partner in the drug development lifecycle. This includes preclinical, clinical, and post-approval phases, ensuring that the medicines undergoing testing meet stringent safety and efficacy standards, which is a significant challenge in today's growing demand for faster time-to-market in healthcare innovation. What sets Fortrea apart from many in its industry is its strategic approach to integrating technology with clinical research, leveraging data-driven insights to streamline processes and improve the accuracy of research outcomes. The company generates revenue by entering into contracts with pharmaceutical and biotechnology companies, charging fees for specific research and trial services. Fortrea’s ability to provide tailored solutions that encompass the breadth of clinical services—from design and optimization of clinical studies to statistical analysis and project management—ensures consistent demand for its offerings. In a world where pharmaceutical innovation dictates market share and competitiveness, Fortrea's role in enabling breakthroughs in medical treatments positions it as a cornerstone of the healthcare research community, driving both its relevance and profitability.

FTRE Intrinsic Value
35.3 USD
Undervaluation 45%
Intrinsic Value
Price
F

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
18.5%
=
Gross Profit
513m
/
Revenue
2.8B
What is the Gross Margin of Fortrea Holdings Inc?

Based on Fortrea Holdings Inc's most recent financial statements, the company has Gross Margin of 18.5%.